Investor Ideas #Potcasts; #Cannabis News
and Stocks on the Move; TSX: $WEED.TO,
NYSE: $CGC, TSXV: $N.V, CSE: $PVOT.C
Pt. Roberts, WA; Delta, BC –June 27, 2018
(Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its “potcast’
site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the June 27 podcast:
Read this in full at http://www.investorideas.com/news/2018/cannabis/06276Potcasts-TSX-WEED-NYSE-N-PVOT.asp
Today’s podcast overview/transcript:
Good afternoon and welcome to another Investorideas.com potcast; looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts. Today’s podcast featrues news announcements from Canopy Growth Corporation (TSX:s WEED and the
NYSE: CGC), Namaste Technologies Inc. (TSX-Venture: N ) and Pivot
Pharmaceuticals Inc. (CSE: PVOT and OTCQB: PVOTF) .
First, we
look at Canada’s continued push towards legalization this October.
Today,
Health Canada announced the regulations supporting the Cannabis Act. The Cannabis
Regulations and the new Industrial
Hemp Regulations are based on best practices from the previous
regulations for producers of cannabis for medical purposes and industrial hemp
as well as extensive consultations held over the past several years.
The
regulations include strict specifications for the plain packaging and labelling
and analytical testing of all cannabis products as well as stringent physical
and personnel security requirements for all federally licensed production
sites. They outline details on the licences for cultivation and processing of cannabis,
including micro-size licences, industrial hemp, research and analytical
testing. The regulations also maintain a distinct system for access to cannabis
for medical purposes.
During the
transition between Royal Assent and the coming into force of the Cannabis Act on October 17, 2018, the
Government of Canada will continue to work with the provinces and territories,
Indigenous communities, stakeholders, and regulated parties to promote
understanding of, and compliance with, the regulations and help ensure an
orderly transition to the new legal framework.
The
regulations announced today will be published in the Canada Gazette, Part II, on July 11, 2018, and are available
upon request from Health Canada.
Canopy
Growth Corporation today released its consolidated financial results for the
fourth quarter and fiscal year ended March 31, 2018.
The main highlights from the quarter are:
-
Total licensed footprint exceeding 2.4
million sq. ft.; 200,000 clones prepared and shipped from Ontario to jump start
cultivation in million sq. ft. greenhouses in British Columbia;
-
Inventory of approximately 15,700 kilograms
of dry cannabis, 7,000 litres of cannabis oils and 360 kilograms of softgel
capsules at quarter end;
-
Secured deep channels into Canadian
recreational market; multi-year supply agreements, with commitments totaling
over 25,000 kg per year, with 5 provinces and territories announced to
date; secured private "brick & mortar" and online cannabis retail
licenses in Manitoba, Newfoundland & Labrador and Saskatchewan;
-
Annual and fourth quarter revenue of $77.9
million and $22.8 million, representing year over year increase of 95% and 56%,
respectively;
-
Record Germany quarterly sales of $2.3
million;
-
Approximately $323 million cash on hand at
year end to fund domestic and global expansion.
"With
the recent launch of our Spectrum Softgels, strong sales in Canada and Germany
and the expansion of our global footprint into Africa and further into Europe
and Australia, we continue to drive our global leadership position in medical
cannabis forward," said Bruce Linton, Chairman & Chief Executive
Officer. "The efforts of Canopy Growth and Canopy Health
Innovations to develop a range of patented, insurance coverage eligible
cannabis-based medicines took a critical step forward with the recent receipt
of approval to conduct its first in a planned series of clinical trials.
Believing that combining Canopy Health's growing intellectual property
portfolio with our production and advanced manufacturing platform will speed time
to market of disruptive medicines, we made the decision to pursue full
ownership of Canopy Health Innovations."
Namaste
Technologies Inc. announced the signing of a Master Services Agreement with YPB
Group Ltd., an Australian based product verification and customer engagement
company. Namaste has identified the need for its global customers to have
confidence in the products they are purchasing, and for vendors to have access
to granular data on their end-users. As such, Namaste plans to introduce
YPB's solutions across its network of manufacturers and to Canadian Licensed
Producers to bring certainty of authenticity and supply chain transparency to
the entire legal cannabis industry globally. This coalition furthers Namaste's
agenda in providing leading technology platforms for its global marketplace and
in enhancing the user's experience for its customers.
Pivot
Pharmaceuticals Inc. announce that it will file an Investigational New Drug
(IND) application with the U.S. Food and Drug Administration (FDA) and Clinical
Trial Application (CTA) with Health Canada to begin human clinical trials of
PVT-005, the Company's pharmaceutical drug candidate for the treatment of
Female Hypoactive Sexual Desire Disorder (HSDD).
HSDD, the
most common type of female sexual dysfunction ("FSD"), affects
approximately 12 million women in the U.S. alone. The condition is
characterized by low sexual desire and marked distress which are not
attributable to existing medical, pharmacologic, psychiatric, or relationship
issues. Approximately 6 million pre-menopausal women meet the diagnosis for
acquired, generalized HSDD.
Using
Pivot's drug formulation and delivery platform technologies, the Company will
develop and aim to commercialize a topical cream containing cannabinoids ("PVT-N005")
for perimenopausal, menopausal and post-menopausal women who have noticed a
decline in sexual desire and response. While erectile dysfunction in men has
been extensively researched, very little has been completed on female sexual dysfunction
which can involve reduced sex drive, difficulty becoming aroused, vaginal
dryness, lack of orgasm and decreased sexual satisfaction.
Investor ideas reminds
all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on
iTunes, Google Play Music, Stitcher and Tunein.
Potcasts is now a certified word
mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires
Big Ideas
Investorideas.com is
a meeting place for global investors, featuring news, stock directories, video,
company profiles, interviews and more in leading sectors.
Investorideas.com
cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the
Investorideas.com news and stock directory pages, a cannabis investor group on
Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site Global Cannabis Investing at www.Globalcannabisinvesting.com
Disclaimer/Disclosure: Investorideas.com is
a digital publisher of third party sourced news, articles and equity research
as well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases or
sale of stocks, services or products. Nothing on our sites should be construed
as an offer or solicitation to buy or sell products or securities. All
investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment